Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT31: GNOS-PV02 and INO-9012 vs Active Surveillance in High-Risk HCC
NCT07722741Phase 2Recruiting
- Sponsor
- Geneos Therapeutics
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 2
01
Overview
A Phase 2 trial of GNOS-PV02 in hepatocellular carcinoma (HCC), sponsored by Geneos Therapeutics. Started Sep 2026; status: recruiting.
02
Drugs
GNOS-PV02
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07722741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07722741.